Merck's hepatitis C drug boceprevir gains FDA panel's support

04/27/2011 | Wall Street Journal, The

An FDA panel of outside experts unanimously endorsed the approval of Merck & Co.'s boceprevir, saying the drug candidate marks an advance in the treatment of hepatitis C. The panel affirmed clinical data showing the efficacy of boceprevir in combination with standard medicines ribavirin and pegylated interferon. Merck proposed to commercialize it as Victrelis.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Actuary
Meridian Health Plan
Detroit, MI
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX